Compositions and Methods to Inhibit HPV Infection
AssigneeUniversity of Southern California
InventorW. Martin Kast
Life of this patent
Estimating the term…
Abstract
This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection. It also provides methods to design antiviral and/or anticancer agents for cancers that harbor HPV.
Claims13
A method for inhibiting human papillomavirus (HPV) infection of a Langerhans cell (LC) or a tissue containing a LC, comprising administering to the LC or the tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection.
A method for treating or preventing HPV infection in a subject having or at risk of HPV infection, comprising administering to the subject an effective amount of an agent that inhibits HPV binding to ANXA2, thereby preventing or treating HPV infection in the subject.
A method for preventing or inhibiting HPV-related pathologies in a subject having or at risk of an HPV infection, comprising administering to the subject an effective amount of an agent that inhibits HPV binding to ANXA2, thereby preventing or treating HPV-related pathologies in the subject.
A method to determine if a test agent is suitable for one or more of:
- inhibiting or preventing HPV infection of a LC or a tissue containing a LC, or as an antiviral or anticancer agent for cells or tissue that harbor HPV, the method comprising
- (a) administering to a first tissue sample an amount of the test agent;
- (b) administering to a second tissue sample an effective amount of an agent that inhibits binding of HPV to ANXA2;
- and
- (c) comparing the binding, uptake, or gene expression of HPV in the first tissue sample to the binding, uptake, or gene expression in the second tissue sample and/or third tissue sample, wherein the test agent is determined as suitable as one or more of:
- an antiviral, as an anticancer agent or for inhibiting or preventing HPV infection of a LC or a tissue containing a LC if the HPV viral titer of the first tissue sample is similar to the second tissue sample.
Dependencies are inferred from the claim text.